Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
At least 15 dual-payload ADCs will be discussed.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
